No Data
No Data
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Cantor Fitzgerald Reiterates Overweight on Roivant Sciences
Roivant Sciences' (NASDAQ:ROIV) Performance Raises Some Questions
Buy Rating Justified by Roivant Sciences' Growth Prospects and Strategic Pipeline Expansion
Piper Sandler Keeps Their Buy Rating on Roivant Sciences (ROIV)
HC Wainwright & Co. : The Roivant Sciences (ROIV.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $18.00 to $18.00.
HC Wainwright & Co. : The Roivant Sciences (ROIV.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $18.00 to $18.00.